Evidence to Practice
January 2016

Proprotein Convertase Subtilisin/Kexin Type 9 (PCSK9) Inhibitors for Treatment of High Cholesterol LevelsEffectiveness and Value

Author Affiliations
  • 1Division of General Internal Medicine, Department of Medicine, University of California, San Francisco
  • 2Division of Cardiology, Department of Medicine, University of California San Francisco
  • 3Department of Epidemiology and Biostatistics, University of California, San Francisco
  • 4Center for Healthcare Value, University of California, San Francisco
  • 5Institute for Clinical and Economic Review, Boston, Massachusetts

Copyright 2016 American Medical Association. All Rights Reserved. Applicable FARS/DFARS Restrictions Apply to Government Use.

JAMA Intern Med. 2016;176(1):107-108. doi:10.1001/jamainternmed.2015.7248

The Institute for Clinical and Economic Review developed an evidence report, including a systematic review of the literature, a cost-effectiveness model, and a budget impact assessment, to support a public meeting of the New England Comparative Effectiveness Public Advisory Council (CEPAC) on October 27, 2015.1 The report evaluates the comparative clinical effectiveness and comparative value of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitors as a class for the treatment of adults with familial hypercholesterolemia or cardiovascular disease (CVD) who require additional lowering of low-density lipoprotein cholesterol (LDL-C) levels.

First Page Preview View Large
First page PDF preview
First page PDF preview